Trial · NCT07187505
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
NCT07187505, Not applicable, Active not recruiting, Anhui Medical University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia. Trials, record NCT07187505. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07187505
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
- NCT number
- NCT07187505
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 28 participants, estimated
- Lead sponsor
- Anhui Medical University
- Conditions
- Acute Promyelocytic Leukemia (APL)
- Interventions
- Venetoclax, All-trans retinoic acid, Arsenic Trioxide (ATO)
- First posted
- 2025-09-23
- Last updated
- 2025-09-23
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Early Mortality (Day 0-30) | 30 days | Proportion of patients who die from any cause within 30 days after treatment initiation. |
| Secondary | Incidence of Complications | 30 days | Proportion of patients experiencing severe complications related to induction therapy. |
| Secondary | Event-Free Survival (EFS) | Up to 2 years | Time from enrollment to treatment failure, relapse, or death from any cause. |
| Secondary | Overall Response Rate (ORR) | At 3 months after induction therapy | Proportion of patients achieving overall response, defined as complete remission (CR) plus partial remission (PR). |
| Other | Changes in Daily White Blood Cell Count During Induction | 30 days | Monitoring daily white blood cell (WBC) counts during the induction phase. |
| Other | Incidence of Laboratory Abnormalities | From enrollment through 2 years. | Frequency of grade 3-4 abnormal laboratory test results according to CTCAE. |
| Other | Incidence of Differentiation Syndrome | 30 days | Proportion of patients developing differentiation syndrome during induction therapy. |
| Other | Frequency of Blood Product Transfusion | 30 days | Number of blood or platelet transfusions during induction therapy. |
| Other | Volume of Blood Product Transfusion | 30 days | Total amount of blood or platelet transfused (units or mL) during induction therapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07187505
GET https://conductscience.org/api/trials/v1/NCT07187505/registered